Q-omics provides the consensus-scored ALG10 profile across patient tissues and cancer cell-line models. ALG10 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ALG10 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ALG10 RNA expression shows 20,773 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where ALG10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALG10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALG10 survival associations across molecular data types. ALG10 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALG10 RNA expression–survival associations across cancer types. High ALG10 expression shows unfavorable associations in ACC, LIHC, LGG and UVM, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ALG10 RNA expression.
This table summarizes ALG10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ALG10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALG10 shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, STAD, LUAD and KIRP. The HNSC box plot shows higher ALG10 RNA expression in tumor versus normal tissue (log2 FC = +0.726, t-test p < 0.001).
This table shows molecular features associated with ALG10 in patient tissues and cancer cell lines. In patient samples, ALG10 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ALG10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
